Active, not recruitingPhase 3NCT03383458
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Studying Adult hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bristol-Myers Squibb
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- Nivolumab(biological)
- Enrollment
- 545 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2031
Study locations (30)
- Local Institution - 0081, Anniston, Alabama, United States
- Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
- Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
- Local Institution - 0135, Los Angeles, California, United States
- Local Institution - 0088, Palo Alto, California, United States
- Local Institution - 0085, San Francisco, California, United States
- Local Institution - 0235, Aurora, Colorado, United States
- Local Institution - 0267, Miami, Florida, United States
- Sylvester Comprehensive Cancer Center/ UMHC, Miami, Florida, United States
- Local Institution - 0163, Tampa, Florida, United States
- Local Institution - 0009, Atlanta, Georgia, United States
- Local Institution - 0025, Westwood, Kansas, United States
- Local Institution - 0086, New Orleans, Louisiana, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Ono Pharmaceutical Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03383458 on ClinicalTrials.govOther trials for Adult hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07441369Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerFudan University
- RECRUITINGPHASE2NCT07175441Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRiboscience, LLC.
- RECRUITINGPHASE2NCT07560488Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE1, PHASE2NCT07291076A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Bristol-Myers Squibb
- RECRUITINGPHASE2NCT07010497A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular CarcinomaAsan Medical Center
- RECRUITINGPHASE1, PHASE2NCT07500220Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCCBeijing Biotech
- RECRUITINGPHASE2NCT07413354Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaTongji Hospital
- RECRUITINGNANCT07365527Sonoporation and Tumor Microenvironment Response in Colorectal Liver MetastasesZealand University Hospital